REG - Tissue Regenix Group - European patent granted

Tissue RegenixAnnouncement

27/03/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250327:nRSa3920Ca&default-theme=true

RNS Number : 3920C  Tissue Regenix Group PLC  27 March 2025

 

Tissue Regenix Group plc

('Tissue Regenix', the 'Group' or the 'Company')

 

European patent granted

Further protecting the Company's proprietary decellularisation technology

 

Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces
it has been granted a European patent (EP4114476) by the European Patent
Office for the Company's innovative decellularisation technology (dCELL®).
The patent relates to the method for producing decellularisation tissue
scaffold which is a foundation for Tissue Regenix's platform and plays a
pivotal role in the development of its product range.

 

This development marks another significant milestone in the protection and
commercial strength of the Company's intellectual property portfolio and
reinforces the Company's commitment to innovation and leadership in the
industry, as the Group expands its footprint in the global regenerative
medicine and implantable device markets. This patent adds to those the Company
already has granted in the U.S. and U.K. for its dCELL technology.

 

The Group's dCELL technology platform removes DNA and other cellular material
from animal and human soft tissue, leaving an acellular tissue scaffold, which
supports tissue growth and remodeling, is not rejected by the patient's body,
and can then be used to repair diseased or damaged body parts.

 

Daniel Lee, CEO of Tissue Regenix, said: "Securing this patent is a
significant achievement for the Company. It reflects the continuation of the
strength of our innovation and the differentiated value we bring to the
market. This protection is key as we continue to scale and build long-term
value for patients, partners, and shareholders."

 

For more information, please contact:

 

 Tissue Regenix Group plc
 Daniel Lee, Chief Executive Officer          via Walbrook PR
 David Cocke, Chief Financial Officer

 Cavendish Capital Markets (Nominated Adviser and Broker)                         Tel: +44 (0) 20 7466 5000
 Geoff Nash/Giles Balleny/Edward Whiley
 Nigel Birks - Life Science Specialist Sales
 Harriet Ward - ECM

 Walbrook PR (Financial PR and IR)            Tel: +44 (0)20 7933 8780
 Alice Woodings / Lianne Applegarth           Tissue Regenix@walbrookpr.com (mailto:TissueRegenix@walbrookpr.com)

 

About Tissue Regenix (www.tissueregenix.com (http://www.tissueregenix.com) )

Tissue Regenix is a leading medical device company in regenerative medicine.
The Company's patented decellularisation technology (dCELL®) removes DNA and
other cellular material from animal and human soft tissue, leaving an
acellular tissue scaffold that is not rejected by the patient's body and can
be used to repair diseased or damaged body structures. Current applications
address many crucial clinical needs in sports medicine, foot and ankle
injuries and wound care.

 

In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech
company specialises in regenerative medicine and is dedicated to developing
high-quality, innovative tissue scaffolds to enhance healing opportunities in
defects created by trauma and disease. CellRight's human tissue products may
be used in spine, trauma, general orthopaedic, dental and ophthalmological
surgical procedures.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLFVAVVIRFIE